• OPEN AN ACCOUNT
Indian Indices
Sensex
82,566.37 221.69
( 0.27%)
Global Indices
Nasdaq
49,020.90 -412.51
(-0.83%)
Dow Jones
6,999.25 28.02
(0.40%)
Hang Seng
53,521.14 162.43
(0.30%)
Nikkei 225
10,179.25 24.82
(0.24%)
Forex
USD-INR
91.63 -0.01
(-0.02%)
EUR-INR
109.29 0.55
(0.50%)
GBP-INR
125.84 0.55
(0.44%)
JPY-INR
0.60 0.00
(0.30%)

EQUITY - MARKET SCREENER

Mahindra & Mahindra Ltd
Industry :  Automobiles - Passenger Cars
BSE Code
ISIN Demat
Book Value()
500520
INE101A01026
534.8629059
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
M&M
30.62
428849.57
EPS(TTM)
Face Value()
Div & Yield %
112.61
5
0.71
 

alka india ltd
Astrazeneca Pharma and Sun Pharma form second brand partnership
Nov 17,2025
Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma® whereas Sun Pharma will promote and distribute the therapy as Gimliand®. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.